Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affimed Therapeutics has entered into a collaboration under which its antibodies will be enhanced with InNexus Biotechnology's SuperAntibody drug development platform to target multiple cancers.
Subscribe to our email newsletter
After the companies complete feasibility studies, InNexus will have a right to license one of Affimed’s antibodies, while Affimed will have the right to license the SuperAntibody technology for the development of one antibody.
Exercise of rights are expected to trigger payments in the form of licensing fees, milestone payments and sales royalty.
“This is a unique product development opportunity for both companies, leveraging Affimed’s antibody generating capability with the potency-enhancing SuperAntibody Technology of InNexus,” said Dr Charles Morgan, president & chief scientific officer of InNexus. “This is a win-win relationship and provides us with the first candidate, targeting colon cancer, to enter our SuperAntibody bioequivalent program.”
InNexus recently announced its SuperAntibody bioequivalent program which is designed to create enhanced versions of existing FDA-cleared antibodies.